Investor Presentaiton

Research framework in action: anti-CCR8 antibody depletes T regulatory cells (Tregs) with combination potential Transformational potential First-in-class, Treg-depleting monoclonal antibody (mAb) with broad combo potential across multiple tumor types. Causal human biology Clinical trial translational data demonstrate CCR8+ regulatory T cells (T regs) are a major barrier to effective immune response to anti-PD1 therapy in multiple cancer types. Hypothesis: Matching modality to mechanism BMS-986340 is an anti-CCR8 IgG1 biologic with enhanced non-fucosylated (NF) Fc that binds CCR8 and potently depletes T regs while sparing effector CD8 T cells. Path to clinical proof-of-concept Depletion of CCR8+ Tregs in the tumor after 2 cycles Reduced ratio CCR8 Treg to CD8+ Teff in the tumor 1.5 Anti-CCR8 mAb Deplete CCR8+ Treg Ill Bristol Myers Squibb™ Anti-PD1 mAb Reduce ratio, remove brake Activated CD8 T cell Activated anti-tumor response Tumor cell killing Treatment Screening CCR8:CD8 ratio 1.0. 0.5- 0.0 Screening C2D5 Not for Product Promotional Use 27

View entire presentation